{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:48:34Z","timestamp":1773816514355,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-02-09"],"award-info":[{"award-number":["2024SF-ZDCYL-02-09"]}],"id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-YBSF-292"],"award-info":[{"award-number":["2023-YBSF-292"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["M2022-3"],"award-info":[{"award-number":["M2022-3"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52203337"],"award-info":[{"award-number":["52203337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102976"],"award-info":[{"award-number":["82102976"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007938","name":"Qingdao University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007938","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ebiom.2025.106026","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:09:32Z","timestamp":1763359772000},"page":"106026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PROTAC-mediated structure\u2013function disruption of CD26: a therapeutic strategy for driver-negative non-small cell lung cancer"],"prefix":"10.1016","volume":"122","author":[{"given":"Guangjian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deqian","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingzhuo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5459-4318","authenticated-orcid":false,"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.106026_bib1","article-title":"Current treatments for non-small cell lung cancer","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106026_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106026_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"10.1016\/j.ebiom.2025.106026_bib4","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106026_bib5","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106026_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1758834011427927","article-title":"Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians","volume":"4","author":"Wang","year":"2012","journal-title":"Ther Adv Med Oncol"},{"issue":"25","key":"10.1016\/j.ebiom.2025.106026_bib7","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2025.106026_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-Positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.ebiom.2025.106026_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106026_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106026_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ebiom.2025.106026_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105739","article-title":"Targeting Stat3 with conditional knockout or PROTAC technology alleviates renal injury by limiting pyroptosis","volume":"116","author":"Ji","year":"2025","journal-title":"eBioMed"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106026_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ebiom.2025.106026_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105212","article-title":"Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy","volume":"105","author":"Zhang","year":"2024","journal-title":"eBioMed"},{"key":"10.1016\/j.ebiom.2025.106026_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105162","article-title":"Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response","volume":"104","author":"Xu","year":"2024","journal-title":"eBioMed"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106026_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"12","key":"10.1016\/j.ebiom.2025.106026_bib17","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106026_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106026_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbrc.2018.09.169","article-title":"Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)","volume":"505","author":"Kang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"34","key":"10.1016\/j.ebiom.2025.106026_bib20","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106026_bib21","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ebiom.2025.106026_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","article-title":"CD26\/DPP4\u2014a potential biomarker and target for cancer therapy","volume":"198","author":"Enz","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106026_bib23","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/cam4.2278","article-title":"Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a Surveillance Epidemiology and Endpoint Research Medicare study","volume":"8","author":"Bishnoi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ebiom.2025.106026_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13046-018-0869-1","article-title":"Downregulating CD26\/DPPIV by apigenin modulates the interplay between Akt and Snail\/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses","volume":"37","author":"Chang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.ebiom.2025.106026_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202506950","article-title":"EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106026_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/carcin\/bgz009","article-title":"The CD26\/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity","volume":"40","author":"Jang","year":"2019","journal-title":"Carcinogenesis"},{"issue":"22","key":"10.1016\/j.ebiom.2025.106026_bib27","doi-asserted-by":"crossref","first-page":"19720","DOI":"10.1074\/jbc.M111901200","article-title":"Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26\/dipeptidyl peptidase IV","volume":"277","author":"Richard","year":"2002","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106026_bib28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00262-014-1553-8","article-title":"Extracellular adenosine metabolism in immune cells in melanoma","volume":"63","author":"Umansky","year":"2014","journal-title":"Cancer Immunol Immun"},{"issue":"63","key":"10.1016\/j.ebiom.2025.106026_bib29","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1039\/C8CC05048A","article-title":"A novel non-enzymatic hydrolytic probe for dipeptidyl peptidase IV specific recognition and imaging","volume":"54","author":"Xing","year":"2018","journal-title":"Chem Commun"},{"key":"10.1016\/j.ebiom.2025.106026_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2025.100221","article-title":"Design and development of PROTACs: a new paradigm in anticancer drug discovery","volume":"27","author":"Mathur","year":"2025","journal-title":"Med Drug Discov"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106026_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166275","article-title":"Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs-An Ab initio fragment molecular orbital study","volume":"11","author":"Arulmozhiraja","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106026_bib32","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/acschembio.5b00143","article-title":"NanoBRET\u2014a novel BRET platform for the analysis of protein-protein interactions","volume":"10","author":"Machleidt","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106026_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.molcel.2020.06.023","article-title":"RNF126-mediated reubiquitination is required for proteasomal degradation of p97-extracted membrane proteins","volume":"79","author":"Hu","year":"2020","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106026_bib34","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ebiom.2025.106026_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70726","article-title":"Targeting DNA topoisomerases or checkpoint kinases results in an overload of chaperone systems, triggering aggregation of a metastable subproteome","volume":"11","author":"Huiting","year":"2022","journal-title":"ELife"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106026_bib36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.cdd.4400938","article-title":"DNA damage and apoptosis","volume":"8","author":"Wang","year":"2001","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106026_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","article-title":"DNA damage-induced cell death by apoptosis","volume":"12","author":"Roos","year":"2006","journal-title":"Trends Mol Med"},{"issue":"16","key":"10.1016\/j.ebiom.2025.106026_bib38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2165\/0003495-200868160-00009","article-title":"Vildagliptin: a review of its use in the management of type 2 diabetes mellitus","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106026_bib39","first-page":"e23","article-title":"Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106026_bib40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.tips.2016.09.003","article-title":"EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?","volume":"37","author":"Ke","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ebiom.2025.106026_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ebiom.2025.106026_bib42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.1998.tb01570.x","article-title":"Dipeptidyl-peptidase IV\/CD26 on T cells: analysis of an alternative T-cell activation pathway","volume":"161","author":"von Bonin","year":"1998","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1016\/j.ebiom.2025.106026_bib43","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J Am Chem Soc"},{"issue":"17","key":"10.1016\/j.ebiom.2025.106026_bib44","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cbic.200700438","article-title":"Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool","volume":"8","author":"Lee","year":"2007","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106026_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.jcim.1c01036","article-title":"Impact of PROTAC linker plasticity on the solution conformations and dissociation of the ternary complex","volume":"62","author":"Weerakoon","year":"2022","journal-title":"J Chem Inf Model"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106026_bib46","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106026_bib47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","article-title":"ATP and adenosine metabolism in cancer: exploitation for therapeutic gain","volume":"74","author":"Yegutkin","year":"2022","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106026_bib48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/biom12030418","article-title":"Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer","volume":"12","author":"Zhulai","year":"2022","journal-title":"Biomolecules"},{"issue":"30","key":"10.1016\/j.ebiom.2025.106026_bib49","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1093\/eurheartj\/ehab316","article-title":"DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells","volume":"42","author":"Wang","year":"2021","journal-title":"Eur Heart J"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:50:26Z","timestamp":1773813026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425004700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S2352396425004700"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106026","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTAC-mediated structure\u2013function disruption of CD26: a therapeutic strategy for driver-negative non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106026"}}